Scientific Publications

The links on this page are not affiliated with Mitsubishi Tanabe Pharma America, Inc. (MTPA). Links to sites outside of MTPA are provided as a resource to the viewer. MTPA accepts no responsibility for the content of linked sites. Some links may direct to third-party websites that require a subscription to access publications.

Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis
Brooks BR, Berry JD, Ciepielewska M, et al. eClinicalMedicine. 2022;52:101590.
View Publication
Edaravone administered orally and via nasogastric tube in healthy adults: a comparative bioavailability phase 1 study
Shimizu H, Nishimura Y, Shiide Y. Clin Pharmacol Drug Dev. Published online Oct 12, 2022. doi:10.1002/cpdd.1175
View Publication
Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19)
Shefner J, Heiman-Patterson T, Pioro EP, et al. Muscle Nerve. 2020;61(2):218-221.
View Publication
Analysis of the US safety data for edaravone (Radicava®) from the third year after launch
Genge A, Brooks BR, Oskarsson B, et al. Drugs R D. 2022;22(3):205-211. doi:10.1007/s40268-022-00391-6
View Publication
Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of Study 19 (MCI186-19)
[clinical trial NCT01492686]
Brooks BR, Heiman-Patterson T, Wiedau-Pazos M, et al. PloS One. 2022;17(6):e0258614.
View Publication
Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study
Berry JD, Bedlack R, Mathews D, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(1-2):147-150. doi:10.1080/21678421.2020.1804939
View Publication
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool
Brooks BR, Pioro EP, Beaulieu D, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(1-2):49-57. doi:10.1080/21678421.2021.1927102
View Publication
Clinical staging in amyotrophic lateral sclerosis: analysis of edaravone Study 19
Al-Chalabi A, Chiò A, Merrill C, et al. J Neurol Neurosurg Psychiatry. 2021;92(2):165-171.
View Publication
Treatment persistence among amyotrophic lateral sclerosis patients receiving intravenous edaravone: results from a national infusion center
Hagan M, Ciepielewska M, Harrison A, et al. Poster presented at virtual 31st International Symposium on ALS/MND; December 9-11, 2020.
View Publication
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Lancet Neurol. 2017;16(7):505-512. doi:10.1016/S1474-4422(17)30115-1
View Publication
Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis
Palumbo JM, Hubble J, Apple S, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5-6):421-431. doi:10.1080/21678421.2019.1599955
View Publication
A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis
The Edaravone (MCI-186) ALS 16 Study Group. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Sup1):11-19. doi:10.1080/21678421.2017.1363780
View Publication
Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects
Shimizu H, Nishimura Y, Shiide Y, et al. Clin. Pharmacol. Drug Dev. 2021; 10: 1188-1197. doi: 10.1002/cpdd.952
View Publication
Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults
Shimizu H, Nishimura Y, Shiide Y, et al. Clin. Pharmacol. Drug Dev. 2021; 10: 1174-1187. doi: 10.1002/cpdd.925
View Publication
Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants
Hidetoshi H, Nishimura Y, Shiide Y, et al. Clin. Ther., Volume 44, Issue 12, 2022, Pages 1552-1565, ISSN 0149-2918. doi: 10.1016/j.clinthera.2022.10.001.
View Publication
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
Abe K, Itoyama Y, Sobue G, et al. 2014. Amyotroph Lateral Scler Frontotemporal Degener, 15(7-8):610-617. doi: 10.3109/21678421.2014.959024
View Publication
Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study
Shimizu H, Nishimura Y, Shiide Y, et al. Clin. Pharmacol. Drug Dev. 2023. 12: 77-84. Doi: 10.1002/cpdd.1175
View Publication